Senior scientist and team leader in the Cell Engineering department at Sangamo Therapeutics France, the French subsidiary of a Sangamo Therapeutics, a US genomic medicines company. 𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 :- Management of research projects - Design and management of preclinical studies- Team leader (direct management of up to 1 engineer, 1 assistant engineer and 1 lab technician)𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:Our mission is to apply… Show more Senior scientist and team leader in the Cell Engineering department at Sangamo Therapeutics France, the French subsidiary of a Sangamo Therapeutics, a US genomic medicines company. 𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 :- Management of research projects - Design and management of preclinical studies- Team leader (direct management of up to 1 engineer, 1 assistant engineer and 1 lab technician)𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:Our mission is to apply cutting-edge technologies (Zinc Finger, AAV, lentiviral tools) and innovative approaches to develop new cell and gene therapies for a variety of disorders:- Preclinical CAR-Treg programs for autoimmune diseases (IBD and multiple sclerosis).- Anti-tumor activity of CAR-T cells using ZF repressors targeting exhaustion markers- Engineered B cells secreting therapeutic levels of human Factor IX to treat hemophilia B𝐊𝐞𝐲 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬: - 2 publications [Mol. Ther. Methods Clin Dev. 2023 and BioRxiv 2024] (+2 currently under submission)- 8 presentations in international congresses [CIMT 2024, ECCO 2024, ESGCT 2023-2022-2021, ASGCT 2023-2022, Keystone Symposium 2003] Show less

Scientist and team leader in the Preclinical Pharmacology and Safety department at TxCell (innovative and personalized cell immunotherapies using regulatory T-cells)𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Management of research projects - Design and management of preclinical studies- Team leader (direct management of up to 1 engineer and 1 lab technician)𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:Preclinical development of cell immunotherapy using regulatory… Show more Scientist and team leader in the Preclinical Pharmacology and Safety department at TxCell (innovative and personalized cell immunotherapies using regulatory T-cells)𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Management of research projects - Design and management of preclinical studies- Team leader (direct management of up to 1 engineer and 1 lab technician)𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:Preclinical development of cell immunotherapy using regulatory T-cells (CAR-Treg) for transplantation:- Evaluation of efficacy in Graft-versus-host-disease models- Evaluation of specific tolerance in solid organ transplantation models𝐊𝐞𝐲 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:- Managed the preclinical program to prepare for the first-in-human study of a CAR-Treg candidate (TX200, STEADFAST clinical trial) - 1 publication [Gene Ther 2023] - 2 presentations in international conferences [ESGCT 2017] Show less

Collaboration between Affichem company (development of molecules for the treatment of cancer) and Cancer Research Centre of Toulouse (France).𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Project design and management- Team management (direct management of a junior scientist, an engineer, and a technician).𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬 𝐚𝐧𝐝 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:Preclinical development of a new drug-candidate called Dendrogenin A (DDA AF122) that shows… Show more Collaboration between Affichem company (development of molecules for the treatment of cancer) and Cancer Research Centre of Toulouse (France).𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Project design and management- Team management (direct management of a junior scientist, an engineer, and a technician).𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬 𝐚𝐧𝐝 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:Preclinical development of a new drug-candidate called Dendrogenin A (DDA AF122) that shows strong anticancer effects against leukemic cells from primary patients samples and chemoresistant cell lines in order to reach a phase I clinical trial for Acute Myeloid Leukemia (AML) treatment : - studies on DDA action mechanism: modulation of Liver X receptor and cytotoxic autophagy in vitro/in vivo. - Follow up of DDA anticancer effects on the tumorigenesis from AML cell lines and on the leukemic engraftment from primary human AML engrafted NSG mice model. 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬:- 5 publications [Nature Communication 2017, Cancer discovery 2017, J. Exp. Med 2016, Blood 2015, Blood Cancer J. 2015]- 4 communications in international congresses [ASH 2014-2013, AACR 2014, Cancer Cell Metabolism 2014, ] Show less

LYOS (UMR1033) Pathophysiology, Diagnosis and Treatment of Bone Diseases (Lyon, France)𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Project design and management.- Management (direct management of a lab technician).𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬 𝐚𝐧𝐝 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:- Determination of specific biomarkers of lysophosphatidic acid receptor 1 and 2 activities. - Transcriptomic and miRNAome analyses on breast and prostate cancer cell lines.-… Show more LYOS (UMR1033) Pathophysiology, Diagnosis and Treatment of Bone Diseases (Lyon, France)𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Project design and management.- Management (direct management of a lab technician).𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬 𝐚𝐧𝐝 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:- Determination of specific biomarkers of lysophosphatidic acid receptor 1 and 2 activities. - Transcriptomic and miRNAome analyses on breast and prostate cancer cell lines.- In vivo experiments: follow up of tumorigenesis and bone metastases development by bioluminescence and radiography. Study of tumors and metastatic bones by histology.𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬:- 1 publication [PloS One 2014]- 2 patents [WO2013121146-A1 and WO2013121160-A1]- 2 communications in international congresses [CABS 2011 and CLARA 2011] Show less

LYOS (UMR1033) Pathophysiology, Diagnosis and Treatment of Bone Diseases (Lyon, France), Debiopham collaboration (molecules in early-stage research, Lausanne, Switzerland).𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Project design and management𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬 𝐚𝐧𝐝 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:Involvement of the Autotaxin (ATX) – Lysophosphatidic acid (LPA) – LPA1 receptor axe in breast cancer metastatic dissemination and osteoclastic… Show more LYOS (UMR1033) Pathophysiology, Diagnosis and Treatment of Bone Diseases (Lyon, France), Debiopham collaboration (molecules in early-stage research, Lausanne, Switzerland).𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬:- Project design and management𝐌𝐚𝐢𝐧 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬 𝐚𝐧𝐝 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:Involvement of the Autotaxin (ATX) – Lysophosphatidic acid (LPA) – LPA1 receptor axe in breast cancer metastatic dissemination and osteoclastic differentiation.- ATX de novo expression or inhibition (shRNA) in human and murine breast cancer cell lines.- Anti-metastatic effect of Debio 0719 (LPA1 receptor pharmacological inhibitor) in vitro/in vivo.- LPA1 receptor role on bone remodeling: in vitro and in vivo osteoclast activities.- In vivo experiments: follow up of tumorigenesis and bone metastases development by bioluminescence and radiography. Study of tumors and metastatic bones by histology.𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬:- 6 publications [J. Biol. Chem 2014, Blood 2014, Lysophospholipid Receptors: Signaling and Biochemistry 2013, BBA 2013, Int. J. Oncol 2012, Pharmacol. Exp. Ther 2011, PloS One 2010] - 4 presentations in international conferences [AACR 2010-2008, IBMS 2010, CABS 2008] Show less

INSERM UMR 664 Mechanisms and Treatments of Bone Metastasis,Expression of ATX and LPA receptors mRNA in primary tumor of breast cancer patient